Backgrounds/Aims: The aim of this study was to investigate the prognostic significance of neutrophyil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), CRP and CA19-9 in patients were diagnosed with pancreatic ductal adenocarcinoma (PDAC) to better verify pre-operative risk stratification and management. Methods: This retrospective study included data from 133 consecutive patients with PDAC, who were treated between 2013 and 2015. PDAC diagnosis was made by cytology or assumed by radiological assessment or surgical resection samples. All clinico-pathological data were retrieved from medical records at our institution. The laboratory data were obtained before any treatment modality. Dates of death were obtained from the central registry. Results: There was a statistically significant relation between radiological staging and CA19-9 and survival (p=0.001, p=0.005) and there are significant differences in CA19-9 level between stage I and III, I and IV, II and III, and II and IV. Both CRP and CA19-9 levels were statistically significantly higher in patients with radiological lymph node metastasis than patients with N0 disease (p=0.037, p=0.026). NLR and CA19-9 levels were also higher in metastatic disease (p=0.032, p=0.007). According to Spearman's correlation analysis, we found in all patients that there was a negative correlation between the survival time and CRP and neutrophil count (p=0.019, p=0.011). Conclusions: Preoperative CRP, CA19-9 and NLR are simple, repeatable, inexpensive and well available marker, can give information on lymph node and solid organ metastasis and survival, give clues to prognosis and be useful in clinical staging of patients with PDAC. 
INTRODUCTION
Although cancer of pancreas has a low incidence of nearly 11/100.000 person-years, it is the fifth most common cancer occurring today in humans. Moreover, it is the fourth among cancer caused deaths due to its poor prognosis rates. 1 Only one fifth of patients are eligible for surgery at presentation. 2 Predictability of patient subgroup with high early recurrence rate may be helpful in appropriate management of the disease. Knowing this information, appropriate time and type of surgical intervention may be selected along with neoadjuvant and adjuvant systemic chemotherapies.
Imaging techniques, such as endoscopic ultrasonography, computed tomography, and magnetic resonance imaging, are widely used in the evaluation of pancreatic ductal adenocarcinoma (PDAC) patients, however, their applications are limited because of their inconsistent sensitivity and specificity. 3, 4 Outcome of PDAC patients are routinely predicted by using conventional prognostic factors determined postoperatively. 5 Therefore, although they are quite expensive, and are presented with technical problems, new potential preoperative prognostic indicators have been under investigation. Some new serum markers, such as MMP7, MUC1 and MUC2, have been proposed in evaluation of PDAC patients. 6, 7 Previous studies indicated that systemic inflammation of host might be helpful in estimation of clinical outcome, and interactions between tumor and host immune system independently, thus promoting tumor cell proliferation, metastasis, and activation of inflammatory cascade. 8 Markers such as neutrophil/lymphocyte ratio (NRL), platelet/ lymphocyte ratio (PRL), and modified Glasgow prognostic score (mGPS) have been proposed to determine systemic inflammation in cancer patients. 9, 10 Although it has not been completely clear, some of potential preoperative prognostic indices may be serum C-reactive protein (CRP) levels, lymphocyte count, PLR and NLR in patients with PDA. [10] [11] [12] In the present study, it was aimed to investigate prognostic roles of pre-operative inflammatory response (platelet, and lymphocyte count; NLR, PLR and serum CRP)
in PDAC patients treated and followed-up in our surgery department.
MATERIALS AND METHODS
This retrospective study included data from 133 consecutive patients with PDAC, who applied to our institution between years 2013 and 2015. Patients, who were diagnosed with PDAC by cytology, or by surgical resection samples, or were assumed to have PDAC by radiological assessment, were included in this study. Rare histological subtypes, such as acinar cell carcinoma and neuroendocrine carcinoma were excluded from the study. All clinico-pathological data were retrieved from medical records at our institution. Tumor staging was performed according to the 7th edition the TNM classification system. 13 Laboratory parameters including neutrophil, and leukocyte counts, CRP and CA19-9 were measured before each treatment modality. Follow-up evaluations were performed every three months within the first three years, six months for five years and annually thereafter for curative resected tumors. Table 2 ).
CRP and also CA19-9 levels were statistically significantly higher in patients with radiological lymph node metastasis than in patients with N0 disease (Mann-Whitney U test; p=0.037 and p=0.026, respectively) ( Table 3) .
NLR and CA19-9 levels were also higher in metastatic disease (Mann-Whitney U p＜0.05) ( Table 2) . Table 3 shows comparison of serum markers in respect to presence of lymph node metastasis on operated patient and there was no significant relation between blood parameters and N0 and N1 disease (Mann-Whitney U, 15 Sierzega et al. 16 reported that NLR might indicate significant prognostic information for patients with resected PDAC, and concluded unfavorable prognosis, which was related to decreased number of immune cells effective against tumor, and increased cell population involved in immune suppression. The aim of this study was to review the evidence for CRP and NLR as prognostic indicators PDAC to determine their benefits in patient management.
Student t p＞0.05). The comparison between pathological
In our study, we determined that both CRP level was statistically significantly higher in patients with radiological lymph node metastasis than in patients with N0 disease, and also NLR level was also higher in metastatic disease. Although it was not demonstrated in our study, PLR elevation was associated with worse survival in various solid tumors. The unfavorable prognosis might be correlated with decreased number of effective immune cells, and increased cell population causing immune suppression. 17 Cheng et al. 18 reported in their meta-analysis, which included 9 cohorts and 2035 patients, that NLR elevation predicted poor prognosis, and shorter overall survival in PDAC patients, and they concluded NLR elevation could be a predictor for poor survival in patients with pancreatic cancer with easy to access, and at a lower cost. In our study, there was a statistically significant correlation between radiological staging and CA19-9 or survival, and there were significant differences in CA19-9 level between stage I and III, I and IV, II and III, and II and IV. In addition, the CA19-9 levels were statistically significantly higher in patients with radiological lymph node metastasis and solid organ metastasis than patients with N0 disease. We highlighted again the preoperative CA 19-9 levels correlated with patient prognosis, and its serum levels were taken into account to decide respectability of PDAC.
Being an acute phase protein produced by the liver as There are some limitations in our study; retrospective design and low quality. Patient cohorts were heterogeneous with regard to presence of associated inflammatory condition, and the use of anti-inflammatory medications.
In addition, lymphocyte and monocyte subpopulations
were not analyzed in our study, and we did not evaluate the functional status of immune cells.
Although these limitations, we found significant differences in CA19-9 level between stage I and III, I and IV, II and III, and II and IV in PDAC. In addition, both CRP and CA19-9 levels were statistically significantly higher in patients with radiological lymph node metastasis than in patients with N0 disease and NLR ratio and CA19-9 levels were also higher in metastatic disease. When patient who underwent operation due to radiological nonmetastatic disease were compared to ones who were not operated, low CRP but higher CA19-9 levels were determined. We also determined in all patients that there was a negative correlation between the survival time, CRP and neutrophil count. As a result, preoperative CRP, CA19-9
and NLR are simple, repeatable, inexpensive and easily available markers, which may well inform about lymph node and solid organ metastasis and survival and provide clues for prognosis and can be useful in clinical staging of patients with PDAC. However, high-quality studies and more multicenter prospective cohorts are required to validate the role of inflammatory mediators.
